BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 38454413)

  • 21. Prognostic impact of programed cell death-1 (PD-1) and PD-ligand 1 (PD-L1) expression in cancer cells and tumor infiltrating lymphocytes in colorectal cancer.
    Li Y; Liang L; Dai W; Cai G; Xu Y; Li X; Li Q; Cai S
    Mol Cancer; 2016 Aug; 15(1):55. PubMed ID: 27552968
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Colorectal Cancer-Derived Small Extracellular Vesicles Promote Tumor Immune Evasion by Upregulating PD-L1 Expression in Tumor-Associated Macrophages.
    Yin Y; Liu B; Cao Y; Yao S; Liu Y; Jin G; Qin Y; Chen Y; Cui K; Zhou L; Bian Z; Fei B; Huang S; Huang Z
    Adv Sci (Weinh); 2022 Mar; 9(9):2102620. PubMed ID: 35356153
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Distinct roles of programmed death ligand 1 alternative splicing isoforms in colorectal cancer.
    Wang C; Weng M; Xia S; Zhang M; Chen C; Tang J; Huang D; Yu H; Sun W; Zhang H; Lai M
    Cancer Sci; 2021 Jan; 112(1):178-193. PubMed ID: 33058325
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Disruption of SIRT7 Increases the Efficacy of Checkpoint Inhibitor via MEF2D Regulation of Programmed Cell Death 1 Ligand 1 in Hepatocellular Carcinoma Cells.
    Xiang J; Zhang N; Sun H; Su L; Zhang C; Xu H; Feng J; Wang M; Chen J; Liu L; Shan J; Shen J; Yang Z; Wang G; Zhou H; Prieto J; Ávila MA; Liu C; Qian C
    Gastroenterology; 2020 Feb; 158(3):664-678.e24. PubMed ID: 31678303
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A Systematic Review of the Tumor-Infiltrating CD8
    Shadbad MA; Asadzadeh Z; Hosseinkhani N; Derakhshani A; Alizadeh N; Brunetti O; Silvestris N; Baradaran B
    Front Immunol; 2021; 12():734956. PubMed ID: 34603316
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Infiltration of tumor-associated macrophages is involved in tumor programmed death-ligand 1 expression in early lung adenocarcinoma.
    Shima T; Shimoda M; Shigenobu T; Ohtsuka T; Nishimura T; Emoto K; Hayashi Y; Iwasaki T; Abe T; Asamura H; Kanai Y
    Cancer Sci; 2020 Feb; 111(2):727-738. PubMed ID: 31821665
    [TBL] [Abstract][Full Text] [Related]  

  • 27. High density of cytotoxic T-lymphocytes is linked to tumoral PD-L1 expression regardless of the mismatch repair status in colorectal cancer.
    Möller K; Blessin NC; Höflmayer D; Büscheck F; Luebke AM; Kluth M; Hube-Magg C; Zalewski K; Hinsch A; Neipp M; Mofid H; Lárusson H; Daniels T; Isbert C; Coerper S; Ditterich D; Rupprecht H; Goetz A; Bernreuther C; Sauter G; Uhlig R; Wilczak W; Simon R; Steurer S; Minner S; Burandt E; Krech T; Perez D; Izbicki JR; Clauditz TS; Marx AH
    Acta Oncol; 2021 Sep; 60(9):1210-1217. PubMed ID: 34092167
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Targeting Interleukin-6 (IL-6) Sensitizes Anti-PD-L1 Treatment in a Colorectal Cancer Preclinical Model.
    Li J; Xu J; Yan X; Jin K; Li W; Zhang R
    Med Sci Monit; 2018 Aug; 24():5501-5508. PubMed ID: 30087314
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Fructose-1,6-bisphosphatase loss modulates STAT3-dependent expression of PD-L1 and cancer immunity.
    Wang B; Zhou Y; Zhang J; Jin X; Wu H; Huang H
    Theranostics; 2020; 10(3):1033-1045. PubMed ID: 31938049
    [No Abstract]   [Full Text] [Related]  

  • 30. Hsa-LINC02418/mmu-4930573I07Rik regulated by METTL3 dictates anti-PD-L1 immunotherapeutic efficacy via enhancement of Trim21-mediated PD-L1 ubiquitination.
    Sun Z; Mai H; Xue C; Fan Z; Li J; Chen H; Huo N; Kang X; Tang C; Fang L; Zhao H; Han Y; Sun C; Peng H; Du Y; Yang J; Du N; Xu X
    J Immunother Cancer; 2023 Dec; 11(12):. PubMed ID: 38040417
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Overexpression of DAPK1-mediated inhibition of IKKβ/CSN5/PD-L1 axis enhances natural killer cell killing ability and inhibits tumor immune evasion in gastric cancer.
    Guo Z; Zhou C; Zhou L; Wang Z; Zhu X; Mu X
    Cell Immunol; 2022 Feb; 372():104469. PubMed ID: 35114597
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Sauchinone Inhibits the Proliferation and Immune Invasion Capacity of Colorectal Cancer Cells through the Suppression of PD-L1 and MMP2/MM9.
    Lu Y; Yu M; Ye J; Liang Y; Gao J; Ji Z; Wang J
    Anticancer Agents Med Chem; 2023; 23(12):1406-1414. PubMed ID: 36941807
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Exosomes-delivered PD-L1 siRNA and CTLA-4 siRNA protect against growth and tumor immune escape in colorectal cancer.
    Li J; Chen Y; Liao M; Yu S; Yuan B; Jia Z; Zhou L; Tang Y
    Genomics; 2023 Jul; 115(4):110646. PubMed ID: 37217085
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Expression and clinical significance of PD-L1 and infiltrated immune cells in the gastric adenocarcinoma microenvironment.
    Quan Q; Guo L; Huang L; Liu Z; Guo T; Shen Y; Ding S; Liu C; Cao L
    Medicine (Baltimore); 2023 Dec; 102(48):e36323. PubMed ID: 38050283
    [TBL] [Abstract][Full Text] [Related]  

  • 35. c-Myb facilitates immune escape of esophageal adenocarcinoma cells through the miR-145-5p/SPOP/PD-L1 axis.
    Zhang L; Wang X; Li Y; Han J; Gao X; Li S; Wang F
    Clin Transl Med; 2021 Sep; 11(9):e464. PubMed ID: 34586738
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Histone Methyltransferase SETDB1 Promotes Immune Evasion in Colorectal Cancer
    Tian J; Wang W; Zhu J; Zhuang Y; Qi C; Cai Z; Yan W; Lu W; Shang A
    J Immunol Res; 2022; 2022():4012920. PubMed ID: 35497876
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Sanguisorbae Radix Suppresses Colorectal Tumor Growth Through PD-1/PD-L1 Blockade and Synergistic Effect With Pembrolizumab in a Humanized PD-L1-Expressing Colorectal Cancer Mouse Model.
    Lee EJ; Kim JH; Kim TI; Kim YJ; Pak ME; Jeon CH; Park YJ; Li W; Kim YS; Choi JG; Chung HS
    Front Immunol; 2021; 12():737076. PubMed ID: 34659228
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Targeting integrin α5 in fibroblasts potentiates colorectal cancer response to PD-L1 blockade by affecting extracellular-matrix deposition.
    Lu L; Gao Y; Huang D; Liu H; Yin D; Li M; Zheng J; Wang S; Wu W; Zhao L; Bi D; Zhang Y; Song F; Xie R; Wang J; Qin H; Wei Q
    J Immunother Cancer; 2023 Dec; 11(12):. PubMed ID: 38040421
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical significance of glycogen synthase kinase 3 (GSK-3) expression and tumor budding grade in colorectal cancer: Implications for targeted therapy.
    Guil-Luna S; Rivas-Crespo A; Navarrete-Sirvent C; Mantrana A; Pera A; Mena-Osuna R; Toledano-Fonseca M; García-Ortíz MV; Villar C; Sánchez-Montero MT; Krueger J; Medina-Fernández FJ; De La Haba-Rodríguez J; Gómez-España A; Aranda E; Rudd CE; Rodríguez-Ariza A
    Biomed Pharmacother; 2023 Nov; 167():115592. PubMed ID: 37778272
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinicopathological significance and prognostic role of tumor-infiltrating lymphocytes in colorectal cancer.
    Ko YS; Pyo JS
    Int J Biol Markers; 2019 Jun; 34(2):132-138. PubMed ID: 30852949
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.